<DOC>
	<DOCNO>NCT00645671</DOCNO>
	<brief_summary>To evaluate clinical safety efficacy Loteprednol Etabonate Ophthalmic Ointment , 0.5 % vs. vehicle treatment inflammation follow cataract surgery</brief_summary>
	<brief_title>Loteprednol Etabonate Ophthalmic Ointment v . Vehicle Treatment Inflammation Following Cataract Surgery</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Loteprednol Etabonate</mesh_term>
	<criteria>1 . Subjects candidate routine , uncomplicated cataract surgery 2 . Subjects , Investigator 's opinion , potential postoperative pinholed Snellen visual acuity ( VA ) least 20/200 study eye . 1 . Subjects require concurrent ocular therapy NSAIDs , mast cell stabilizer , antihistamine , decongestant , immunosuppressant ( e.g. , Restasis ) , ocular systemic corticosteroid 2 . Subjects know hypersensitivity contraindication study drug ( ) components 3 . Subjects monocular pinholed Snellen VA 20/200 bad nonstudy eye 4 . Subjects ocular surgery ( include laser surgery ) study eye within 3 month fellow eye within 2 week prior Screening Visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>